ZDHHC15 Antibody

What is ZDHHC15 and why is it important in research?

ZDHHC15 belongs to the zinc finger DHHC-type palmitoyltransferase family, which plays crucial roles in protein palmitoylation. This post-translational modification affects protein trafficking, stability, and function. ZDHHC15 is particularly significant in neuroscience and cancer research because:

• It participates in various physiological activities in the brain, including regulation of dendritic growth and formation and maturation of excitatory synapses

• It shows significantly upregulated expression in glioma tissues compared to normal brain tissues

• Mutations in ZDHHC15 are associated with X-linked mental retardation type 91 (MRX91)

• It serves as a potential prognostic biomarker in glioma patients

Understanding ZDHHC15's functions provides insights into both normal brain development and pathological processes in diseases like glioma.

What are the typical applications for ZDHHC15 antibodies in research?

ZDHHC15 antibodies are versatile tools that support multiple experimental applications:

These applications enable researchers to investigate ZDHHC15 expression levels, subcellular localization, and potential interactions with other proteins across different experimental models .

What tissue and species reactivity can be expected with commercial ZDHHC15 antibodies?

Based on available research data, ZDHHC15 antibodies show the following reactivity profiles:

ZDHHC15 is primarily membrane-localized, with expression being particularly relevant in neural tissues. When selecting an antibody, verify the specific isoform recognition capabilities as alternatively spliced transcript variants of ZDHHC15 exist .

What is the expected molecular weight of ZDHHC15 in Western blots?

Researchers should be aware of potential discrepancies between calculated and observed molecular weights:

• Calculated molecular weight: 38-39 kDa

• Commonly observed molecular weight: approximately 42 kDa

This discrepancy is not uncommon and may be attributed to:

• Post-translational modifications (PTMs), including phosphorylation (Y97) and acetylation (K107)

• Protein glycosylation

• Altered protein mobility due to hydrophobic regions

• Expression of different isoforms (calculated MWs range from 17-39 kDa)

When troubleshooting unexpected band patterns, consider using positive control lysates from verified cell lines such as U87-MG or HepG2 .

How can ZDHHC15 be effectively silenced or overexpressed for functional studies?

Based on published methodologies, researchers can manipulate ZDHHC15 expression using these validated approaches:

For ZDHHC15 knockdown:

• siRNA transfection using the following sequence has shown effective silencing:

  • Sense: 5'-CCUUCCCUAUGAGGUCUAUTT-3'

  • Antisense: 5'-AUAGACCUCAUAGGGAAGGTT-3'

• Transfection can be performed using jetPRIME® transfection reagent in cell lines like U87 and U251

• Include appropriate negative control siRNA (sense: 5'-UUCUCGAACGUGUCACGUTT-3'; antisense: 5'-ACUUGACACGUUCGGAGAATT-3')

For ZDHHC15 overexpression:

• cDNA for ZDHHC15 can be synthesized and inserted into the pcDNA3.1 vector

• Transfection can be achieved using Lipofectamine 3000 in glioma cell lines

• Verify overexpression using RT-qPCR and Western blot with the following primers:

  • Forward: 5'-TGCCTGGTGACTGTTTTGAG-3'

  • Reverse: 5'-ATGCAGGCCACAAAGAGAAG-3'

These genetic manipulation techniques provide essential tools for investigating ZDHHC15's functional roles in cellular processes.

How can I optimize immunohistochemistry protocols for ZDHHC15 detection in tissue samples?

For optimal ZDHHC15 immunohistochemical detection in paraffin-embedded tissues, follow this validated protocol:

• Deparaffinization and antigen retrieval:

  • Deparaffinize sections completely

  • Perform antigen retrieval using EDTA antigen repair solution (pH 8.0) by boiling for 3 minutes in a microwave oven

  • Cool in pure water to room temperature

• Blocking and antibody incubation:

  • Wash sections with PBST (3 × 5 minutes)

  • Block with peroxidase block solution for 15 minutes

  • Block with 5% goat serum for 15 minutes

  • Incubate with ZDHHC15 primary antibody (1:100 dilution) at 4°C overnight

• Detection and visualization:

  • Wash with PBST (3 × 5 minutes)

  • Incubate with appropriate secondary antibody for 30 minutes

  • Visualize using DAB chromogenic agent

  • Counterstain with hematoxylin

• Scoring system for ZDHHC15 expression:

This standardized scoring system facilitates consistent evaluation of ZDHHC15 expression across different tissue samples .

How does ZDHHC15 contribute to glioma progression, and what signaling pathways are involved?

ZDHHC15 promotes glioma progression through multiple mechanisms:

• Cell cycle regulation and proliferation:

  • Gene Ontology (GO) and KEGG enrichment analyses reveal ZDHHC15 involvement in cell cycle regulation

  • Knockdown of ZDHHC15 inhibits glioma cell proliferation (verified by CCK-8 and EdU assays)

  • Overexpression of ZDHHC15 accelerates cell proliferation

• Cell migration:

  • ZDHHC15 expression positively correlates with glioma cell migration capability

  • Silencing ZDHHC15 suppresses migration potential (demonstrated by transwell assays)

• STAT3 signaling pathway activation:

  • Gene Set Enrichment Analysis (GSEA) indicates ZDHHC15 enrichment in the STAT3 signaling pathway

  • Experimental evidence confirms ZDHHC15 affects STAT3 pathway activation

  • This suggests ZDHHC15 may promote glioma progression partly through modulating STAT3 signaling

These findings collectively establish ZDHHC15 as a potential oncogenic driver in glioma, making it a promising therapeutic target.

How can I resolve discrepancies between expected and observed molecular weights in ZDHHC15 Western blot experiments?

When facing molecular weight discrepancies in ZDHHC15 detection (expected ~39 kDa vs. observed ~42 kDa), consider these troubleshooting approaches:

• Verify antibody specificity:

  • Use multiple antibodies targeting different epitopes when possible

  • Include positive controls from verified cell lines (U87-MG, HepG2, HEK-293)

  • Consider using ZDHHC15 overexpression or knockdown samples as controls

• Account for post-translational modifications:

  • ZDHHC15 undergoes phosphorylation at Y97 and acetylation at K107

  • These modifications can alter protein mobility in SDS-PAGE

  • Consider phosphatase treatment of samples to eliminate phosphorylation-induced mobility shifts

• Optimize sample preparation:

  • Ensure complete denaturation of samples

  • Consider using different lysis buffers to account for ZDHHC15's membrane localization

  • Include protease and phosphatase inhibitors in lysis buffers

• Isoform considerations:

  • Check which isoform your antibody detects (calculated MWs range from 17-39 kDa)

  • Consider RT-PCR analysis to determine which isoforms are expressed in your samples

Remember that protein mobility in SDS-PAGE can be affected by amino acid composition, post-translational modifications, and hydrophobicity, all of which can cause observed molecular weights to differ from calculated values.

What are the best methodologies for evaluating ZDHHC15 as a prognostic biomarker in clinical samples?

To evaluate ZDHHC15's prognostic value in clinical settings, researchers should employ these validated approaches:

Research indicates that higher ZDHHC15 expression correlates with poorer prognosis in glioma patients, supporting its potential as a clinically relevant biomarker .

How can I optimize Western blot conditions for ZDHHC15 detection?

For reliable ZDHHC15 detection via Western blot, consider these optimization strategies:

• Sample preparation considerations:

  • ZDHHC15 is a membrane-localized protein, requiring effective membrane protein extraction

  • Include appropriate detergents in lysis buffers (e.g., NP-40, Triton X-100)

  • Ensure complete denaturation by heating samples to 95°C for 5 minutes

• Antibody selection and dilution:

  • Recommended dilution ranges: 1:500-1:2000 for most commercial antibodies

  • Verify antibody performance with positive control lysates from U87-MG, HepG2, or HEK-293 cells

  • Consider testing multiple antibodies targeting different epitopes

• Blocking and washing optimization:

  • Use 5% non-fat dry milk or BSA in TBST for blocking

  • Extended blocking time (1-2 hours) may reduce background

  • Thorough washing (3-5 times for 5-10 minutes each) with TBST is essential

• Signal detection considerations:

  • For weak signals, consider enhanced chemiluminescence (ECL) substrates with higher sensitivity

  • Longer exposure times may be necessary

  • Secondary antibody concentration may need adjustment based on signal strength

These optimizations should help achieve clear, specific detection of ZDHHC15 at the expected molecular weight range of approximately 38-42 kDa.

What are the common pitfalls when investigating ZDHHC15 function in different cell types?

Researchers should be aware of these common challenges when studying ZDHHC15:

• Cell type-specific expression patterns:

  • ZDHHC15 expression varies significantly across tissues and cell types

  • Always validate baseline expression in your model system before functional studies

  • Brain-derived cell lines typically show higher expression than other tissue-derived lines

• Functional redundancy with other DHHC family members:

  • The human genome encodes 23 DHHC palmitoyltransferases with partially overlapping functions

  • Knockdown of ZDHHC15 alone may result in compensation by other family members

  • Consider examining multiple DHHC proteins simultaneously (particularly ZDHHC4, ZDHHC9, ZDHHC12, and ZDHHC23, which show altered expression in glioma)

• Experimental validation challenges:

  • Confirm knockdown or overexpression at both mRNA and protein levels

  • For siRNA experiments, optimize transfection conditions for each cell line

  • Include appropriate controls to rule out off-target effects

• Substrate identification complexity:

  • ZDHHC15's palmitoylation substrates may differ between cell types

  • Consider using palmitoylation-specific proteomic approaches when investigating novel substrates

By anticipating these challenges, researchers can design more robust experiments to characterize ZDHHC15 function across different experimental systems.

How can ZDHHC15 be targeted therapeutically in glioma and other cancers?

Based on current research findings, these approaches show promise for therapeutic targeting of ZDHHC15:

• Small molecule inhibitors:

  • The ZDHHC-specific inhibitor 2-bromopalmitate has shown efficacy in inhibiting glioma cell proliferation

  • Development of ZDHHC15-specific inhibitors could provide greater selectivity

  • Structure-based drug design targeting the DHHC catalytic domain represents a promising strategy

• RNA interference-based approaches:

  • siRNA sequences targeting ZDHHC15 have demonstrated efficacy in preclinical models

  • Development of modified siRNAs or shRNAs with improved stability and delivery

  • Exploration of CRISPR-Cas9-based gene editing strategies

• Targeting ZDHHC15-regulated pathways:

  • Given ZDHHC15's connection to STAT3 signaling, combination approaches with STAT3 inhibitors may prove effective

  • Identification of critical ZDHHC15 substrates in cancer cells could reveal additional therapeutic targets

  • Restoring normal palmitoylation patterns of cancer-relevant substrates

Future therapeutic development will require greater understanding of ZDHHC15's substrate specificity in cancer contexts and development of tools to monitor palmitoylation status in clinical samples.

What are the emerging techniques for studying protein palmitoylation mediated by ZDHHC15?

Cutting-edge methodologies for investigating ZDHHC15-mediated palmitoylation include:

• Metabolic labeling approaches:

  • Click chemistry-compatible palmitoylation probes (e.g., 17-octadecynoic acid)

  • Pulse-chase experiments to determine palmitoylation dynamics

  • Bioorthogonal labeling strategies for in vivo palmitoylation studies

• Acyl-biotin exchange (ABE) and acyl-resin-assisted capture (Acyl-RAC):

  • These techniques allow for selective enrichment of palmitoylated proteins

  • Can be coupled with mass spectrometry for proteome-wide identification of ZDHHC15 substrates

  • Particularly useful for identifying changes in substrate palmitoylation following ZDHHC15 modulation

• Live-cell imaging of palmitoylation:

  • FRET/BRET-based sensors to monitor palmitoylation in real-time

  • Development of ZDHHC15-specific activity probes

  • Super-resolution microscopy to visualize palmitoylation-dependent protein localization

• Computational approaches:

  • Machine learning algorithms to predict potential ZDHHC15 substrates

  • Molecular dynamics simulations to understand ZDHHC15-substrate interactions

  • Systems biology approaches to map ZDHHC15-dependent palmitoylation networks

These emerging techniques will be essential for understanding the complex roles of ZDHHC15 in both normal physiology and disease states.

What are the most promising research directions for ZDHHC15 antibody applications?

Based on current literature and technological trends, researchers should consider these high-priority directions:

• Development of phospho-specific ZDHHC15 antibodies:

  • ZDHHC15 undergoes phosphorylation at Y97, which may regulate its function

  • Phospho-specific antibodies would enable monitoring of ZDHHC15 activation status

  • Could provide insights into signaling pathways regulating ZDHHC15 activity

• Application in single-cell technologies:

  • Validation of ZDHHC15 antibodies for single-cell proteomic approaches

  • Integration with spatial transcriptomics to map ZDHHC15 expression in complex tissues

  • Development of ZDHHC15 proximity labeling approaches to identify interaction partners

• Biomarker validation studies:

  • Large-scale validation of ZDHHC15 as a prognostic marker across glioma subtypes

  • Correlation with response to specific therapeutic interventions

  • Development of standardized ZDHHC15 detection protocols for clinical laboratories

• Therapeutic monitoring:

  • Using ZDHHC15 antibodies to monitor responses to palmitoylation inhibitors

  • Development of companion diagnostics for future ZDHHC15-targeted therapies

  • Monitoring changes in ZDHHC15 expression during treatment resistance development

These research directions will maximize the utility of ZDHHC15 antibodies while addressing critical gaps in our understanding of ZDHHC15 biology.